Bicalutamide (Casodex®) in the treatment of prostate cancer

  title={Bicalutamide (Casodex{\textregistered}) in the treatment of prostate cancer},
  author={Yves Fradet},
  journal={Expert Review of Anticancer Therapy},
  pages={37 - 48}
  • Y. Fradet
  • Published 1 February 2004
  • Medicine
  • Expert Review of Anticancer Therapy
Prostate cancer is an important healthcare issue in men worldwide. With the advent of prostate-specific antigen screening and improved diagnostic techniques, prostate cancer is now being diagnosed in younger men and at earlier disease stages. As a result, patients often live with their disease for many years after diagnosis. This shift in the patient profile has focused attention to the impact of treatment on quality of life. Medical/surgical castration has traditionally been the mainstay of… 

Striving Toward a Cure for Prostate Cancer.

  • M. SteinT. Jang
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
Data from this trial clearly validate the preclinical studies noted earlier that demonstrate the superiority of enzalutamide over bicalutamide as an antiandrogen and can be used in clinical practice.

Bicalutamide-induced hepatotoxicity: A rare adverse effect

An 81-year-old African American male with metastatic prostate neoplasm presented with nonspecific symptoms along with jaundice of 1-day duration and bicalutamide was discontinued and he showed improvement of clinical and laboratory abnormalities within days.

Impact of bicalutamide, an anti-androgen on rat testis

Treatment with bicalutamide induced various biochemical, histological and immunological changes in rat testis, and non-significant decrease in relative testis weight was caused.

Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities

A group of Brazilian urology and medical oncology experts developed and completed a survey on the diagnosis and treatment of M0 CRPC in Brazil and the results and recommendations presented can be used by Brazilian physicians to support the management of M 0 CRPC patients.

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

The three-dimensional structure demonstrates that the B ring of R-bicalutamide in the W741L mutant is accommodated at the location of the indole ring of Trp-741 in the WT AR bound to dihydrotestosterone.

Development of a Benzopyran‐Containing Androgen Receptor Antagonist to Treat Antiandrogen‐Resistant Prostate Cancer

The AR is a member of the nuclear receptor superfamily of ligand-dependent transcription factors, and the identification of AR antagonists is an important step in the development of therapeutic agents for the treatment of prostate cancer.

1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.

Biological and theoretical evaluation demonstrated that the introduction of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of small molecules with improved overall AR-antagonist activity, and compound 14d displayed promising in vitro antitumor activity.

Combined treatment with bicalutamide and anastrozole in a young boy with peripheral precocious puberty due to McCune-Albright Syndrome.

This report provides further evidence of effectiveness and safety of combined third generation aromatase inhibitors - competitive androgen receptor blockers in male precocious peripheral puberty, firstly employed in male MAS, and contributes to expand the spectrum of disorders in which their employment may reveal promising.

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

Since majority of prostate tumors express wild-type p53, its activation by MDM2 antagonists in combination with androgen depletion may offer an efficacious new approach to prostate cancer therapy.



Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer

It is not yet clear if antiandrogen are of any benefit in downstaging the extent of disease before prostatectomy and/or radiotherapy, but some evidence exist that pure antiandrogens improve survival if combined with other forms of castration.

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.

  • H. ScherC. Liebertz M. Schwartz
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
The difference in outcomes for patients with androgen-independent progression suggests that the specific hormone therapy administered and the response to that therapy can influence the biology of the relapsing tumor and the sensitivity to subsequent therapies.

Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?

Patients with a higher disease burden (PSA >400 ng/ml) may decide that quality of life and symptomatic benefits outweigh the slight survival disadvantage seen in clinical trials and opt for bicalutamide monotherapy as an alternative to castration.

Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program

At the time of the most recently published analysis, the risk of objective clinical progression was significantly reduced in the bicalutamide arm, but further maturation of data is needed to see whether this difference will lead to a survival advantage.

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.

Bicalutamide monotherapy yielded comparable results relative to standard treatment with MAB, induced fewer side effects, and produced a better QOL.